[go: up one dir, main page]

BR9406604A - High dose formulations - Google Patents

High dose formulations

Info

Publication number
BR9406604A
BR9406604A BR9406604A BR9406604A BR9406604A BR 9406604 A BR9406604 A BR 9406604A BR 9406604 A BR9406604 A BR 9406604A BR 9406604 A BR9406604 A BR 9406604A BR 9406604 A BR9406604 A BR 9406604A
Authority
BR
Brazil
Prior art keywords
high dose
dose formulations
mycophenolic acid
mycophenolate mofetil
formulations
Prior art date
Application number
BR9406604A
Other languages
Portuguese (pt)
Inventor
Glenn Jay Samuels
Jung-Chung Lee
Charles Lee
Stephen Berry
Paul Joseph Jarosz
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of BR9406604A publication Critical patent/BR9406604A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mycophenolate mofetil and mycophenolic acid can be conveniently manufactured into high dose oral formulations by the hot melt filling of a supercooled mycophenolate mofetil or mycophenolic acid liquid into a pharmaceutical dosage form. High dose oral pharmaceutical formulations and manufacturing methods therefor are disclosed.
BR9406604A 1993-05-13 1994-05-10 High dose formulations BR9406604A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/061,656 US5455045A (en) 1993-05-13 1993-05-13 High dose formulations
PCT/US1994/005196 WO1994026266A1 (en) 1993-05-13 1994-05-10 High dose formulations

Publications (1)

Publication Number Publication Date
BR9406604A true BR9406604A (en) 1996-01-02

Family

ID=22037233

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9406604A BR9406604A (en) 1993-05-13 1994-05-10 High dose formulations
BR1100723-0A BR1100723A (en) 1993-05-13 1997-05-09 High-dose formulations of mycophenolate mofetil and mycophenolic acid

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR1100723-0A BR1100723A (en) 1993-05-13 1997-05-09 High-dose formulations of mycophenolate mofetil and mycophenolic acid

Country Status (23)

Country Link
US (3) US5455045A (en)
EP (1) EP0697866B1 (en)
JP (1) JP3584037B2 (en)
KR (1) KR100296214B1 (en)
CN (1) CN1045884C (en)
AT (1) ATE187067T1 (en)
AU (1) AU674960B2 (en)
BR (2) BR9406604A (en)
CZ (1) CZ285297B6 (en)
DE (1) DE69421918T2 (en)
DK (1) DK0697866T3 (en)
ES (1) ES2138661T3 (en)
FI (1) FI114286B (en)
GR (1) GR3032021T3 (en)
HU (2) HU226470B1 (en)
IL (1) IL109639A (en)
NO (1) NO308828B1 (en)
NZ (1) NZ266683A (en)
PL (1) PL175583B1 (en)
PT (1) PT697866E (en)
RU (1) RU2135182C1 (en)
TW (1) TW434010B (en)
WO (1) WO1994026266A1 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69013923T2 (en) * 1989-08-17 1995-03-16 Cortecs Ltd., Isleworth MEDICINAL FORMULATIONS.
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
ID18663A (en) * 1996-04-12 1998-04-30 Novartis Ag COMPOSITION OF PHARMACEUTICAL PLATED PHARMACEUTICALS
UA72207C2 (en) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Pharmaceutical formulations of efavirenz and disintegrants providing for increasing dissolution rate and process of manufacturing such tablets or capsules
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
JP2004505886A (en) 2000-02-18 2004-02-26 スィーヴィー　セラピューティクス　インコーポレイテッド Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6677343B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
AU2001239827A1 (en) 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
US7125876B2 (en) * 2002-12-05 2006-10-24 Cv Therapeutics, Inc. Substituted heterocyclic compounds
US7205303B2 (en) * 2003-01-03 2007-04-17 Cv Therapeutics, Inc. Substituted heterocyclic compounds
KR20050092424A (en) * 2003-01-17 2005-09-21 씨브이 쎄러퓨틱스, 인코포레이티드 Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
KR20060065586A (en) * 2003-06-23 2006-06-14 씨브이 쎄러퓨틱스, 인코포레이티드 Urea derivatives of piperazine and piperidine as fatty acid oxidation inhibitors
JP2007514769A (en) 2003-12-18 2007-06-07 シーブイ・セラピューティクス・インコーポレイテッド 1-alkane-2-ol substituted piperazine and piperidine compounds
EP1740564A2 (en) * 2004-04-26 2007-01-10 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Process for preparation of mycophenolic acid and ester derivatives thereof
CA2555461A1 (en) * 2004-04-27 2005-11-10 Teva Gyogyszergyar Zartkoeruen Mukoedo Reszvenytarsasag Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
CN101014584A (en) * 2004-07-20 2007-08-08 特瓦药厂私人有限公司 The preparation method of crystalline mycophenolate sodium mofetil
US7271169B2 (en) * 2004-09-08 2007-09-18 Cv Therapeutics, Inc. Substituted heterocyclic compounds
RU2384332C2 (en) * 2005-01-06 2010-03-20 Си Ви Терапьютикс, Инк. Prolonged release pharmaceutical preparative forms
CN100393312C (en) * 2005-04-18 2008-06-11 吴建梅 Soft capsule of mycophenolic acid or like and its prepn. method
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
AU2007271088A1 (en) * 2006-07-06 2008-01-10 Ares Trading S.A. An oral pharmaceutical composition of an anilinopyrimidine, its preparation and use thereof
WO2008022284A2 (en) * 2006-08-16 2008-02-21 Aspreva Pharmaceuticals Ltd. Compositions and methods for treating vascular, autoimmune, and inflammatory diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
JP2010518170A (en) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド Use of ranolazine for the treatment of coronary microvascular disease
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
WO2008101002A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
EP2170333B1 (en) * 2007-05-31 2013-02-20 Gilead Sciences, Inc. Ranolazine for elevated brain-type natriuretic peptide
US20090076000A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched mycophenolate mofetil
AR068745A1 (en) * 2007-10-08 2009-12-02 Panacea Biotec Ltd A COMPOSITION IN THE FORM OF ORAL PHARMACEUTICAL DOSAGE OF HIGH DOSAGE UNIT OF SODIUM MYCOPHENOLATE, METHOD FOR USING SUCH COMPOSITION AND ITS USES
KR20110013348A (en) * 2008-02-06 2011-02-09 길리애드 사이언시즈, 인코포레이티드 Use of Ranolazine for Pain Treatment
EP2310008A4 (en) * 2008-07-09 2014-03-05 Aspreva Internat Ltd Ph specific solutions of sodium mycophenolic acid for the treatment of eye disorders
EP2326716B1 (en) * 2008-08-26 2015-04-22 Intelligentnano Inc. Enhanced animal cell growth using ultrasound
US9012192B2 (en) * 2008-08-26 2015-04-21 Intelligentnano Inc. Ultrasound enhanced growth of microorganisms
US8962290B2 (en) 2008-08-26 2015-02-24 Intelligentnano Inc. Enhanced animal cell growth using ultrasound
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
EP2391355B1 (en) * 2009-05-19 2017-01-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
WO2010137040A2 (en) 2009-05-28 2010-12-02 Lupin Limited Novel pharmaceutical compositions of ranolazine
MX2012003362A (en) 2009-09-25 2012-06-27 Lupin Ltd Sustained release composition of ranolazine.
TWI508726B (en) 2009-12-21 2015-11-21 Gilead Sciences Inc Method of treating atrial fibrillation
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
KR20230079115A (en) 2020-09-27 2023-06-05 차이나 페트로리움 앤드 케미컬 코포레이션 Disproportionation and transalkylation catalysts, their preparation and applications
CN114456835B (en) 2020-10-22 2023-06-06 中国石油化工股份有限公司 Treatment system and treatment method for gasoline component

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3374146A (en) * 1966-04-18 1968-03-19 American Cyanamid Co Sustained release encapsulation
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
JPS5542995B2 (en) * 1972-02-24 1980-11-04
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3903071A (en) * 1973-05-22 1975-09-02 Lilly Co Eli Mycophenolic acid derivatives
US4002718A (en) * 1974-10-16 1977-01-11 Arnar-Stone Laboratories, Inc. Gelatin-encapsulated digoxin solutions and method of preparing the same
US4145918A (en) * 1976-09-07 1979-03-27 Akzona Incorporated Freeze-thaw indicator
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
CA1125698A (en) * 1978-03-09 1982-06-15 Masaru Yoshida Process for preparing a polymer composition
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
DK164642C (en) * 1984-08-30 1992-12-14 Merrell Dow Pharma PHARMACEUTICAL COMPOSITION CONTAINING TERFENADIN IN THE FORM OF A HEAT MELT FILLED ON Capsules
DE3438830A1 (en) * 1984-10-23 1986-04-30 Rentschler Arzneimittel PHARMACEUTICAL FORM CONTAINING NIFEDIPIN AND METHOD FOR THE PRODUCTION THEREOF
US4820523A (en) * 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
DE3613799C1 (en) * 1986-04-24 1987-09-03 Nattermann A & Cie Use of glycofurol to liquefy pharmaceutical preparations for filling in soft gelatin capsules
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4727069A (en) * 1987-01-30 1988-02-23 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
US5175000A (en) * 1987-06-30 1992-12-29 Vipont Pharmaceutical, Inc. Free amine benzophenanthridine alkaloid compositions
US4936074A (en) * 1988-11-17 1990-06-26 D. M. Graham Laboratories, Inc. Process for preparing solid encapsulated medicament
WO1990011761A1 (en) * 1989-03-31 1990-10-18 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
EP0497977B1 (en) * 1989-10-26 1995-03-15 Nippon Shinyaku Company, Limited Gastric preparation
FR2657257B1 (en) * 1990-01-19 1994-09-02 Rhone Poulenc Sante PROCESS FOR THE PREPARATION OF DRUGS IN THE FORM OF PEARLS.
DE69129459T2 (en) * 1990-08-10 1998-10-15 Anormed Inc IMMUNOSUPPRESSIVE COMPOSITIONS
US5247083A (en) * 1992-07-10 1993-09-21 Syntex (U.S.A.) Inc. Direct esterification of mycophenolic acid
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
US5467037A (en) * 1994-11-21 1995-11-14 International Business Machines Corporation Reset generation circuit to reset self resetting CMOS circuits

Also Published As

Publication number Publication date
FI114286B (en) 2004-09-30
HUT72978A (en) 1996-06-28
CN1122571A (en) 1996-05-15
NO308828B1 (en) 2000-11-06
DE69421918D1 (en) 2000-01-05
PT697866E (en) 2000-04-28
DE69421918T2 (en) 2000-03-30
CZ295495A3 (en) 1996-02-14
HU226470B1 (en) 2008-12-29
AU674960B2 (en) 1997-01-16
ES2138661T3 (en) 2000-01-16
BR1100723A (en) 2000-04-18
JP3584037B2 (en) 2004-11-04
HU9503224D0 (en) 1996-01-29
PL175583B1 (en) 1999-01-29
KR100296214B1 (en) 2001-10-24
EP0697866B1 (en) 1999-12-01
TW434010B (en) 2001-05-16
AU6830194A (en) 1994-12-12
IL109639A0 (en) 1994-08-26
CZ285297B6 (en) 1999-06-16
FI955439L (en) 1995-11-10
NO954546D0 (en) 1995-11-10
JPH08510254A (en) 1996-10-29
US5455045A (en) 1995-10-03
DK0697866T3 (en) 2000-04-17
NZ266683A (en) 1996-08-27
US5472707A (en) 1995-12-05
GR3032021T3 (en) 2000-03-31
ATE187067T1 (en) 1999-12-15
EP0697866A1 (en) 1996-02-28
NO954546L (en) 1995-11-10
CN1045884C (en) 1999-10-27
US5554384A (en) 1996-09-10
WO1994026266A1 (en) 1994-11-24
HU211270A9 (en) 1995-11-28
IL109639A (en) 1998-02-08
KR960702304A (en) 1996-04-27
RU2135182C1 (en) 1999-08-27
PL311654A1 (en) 1996-03-04
FI955439A0 (en) 1995-11-10

Similar Documents

Publication Publication Date Title
BR9406604A (en) High dose formulations
NO177177C (en) Process for the preparation of a liquid dosage form for oral administration of a pharmaceutical substance
ES537022A0 (en) A PROCEDURE FOR THE PREPARATION OF A DRUG FORMULATION FOR INTRAVENOUS INJECTION.
NO863670L (en) PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL PREPARATION OF A HYDROPHOBIC MEDICINE.
DE69331409D1 (en) ORAL 1ALPHA HYDROXYPREVITAMIN D
FI913248A0 (en) CONTROL OF FAST PHARMACEUTICAL DOSAGE FORM.
PT1035834E (en) OSMOTIC DOSE FORMAT COMPREHENDING FIRST AND SECOND COATINGS
IT1212778B (en) PHARMACEUTICAL COMPOSITIONS ANTI-INFLAMMATORY AND / OR ANALGESIC ADAPTERITY, NON ULCEROGENE.
IT1228312B (en) IRRADIATION DEVICE WITH RING EMITTER COLLECTOR AND CYLINDRICAL POINT CROWN DISTRIBUTOR FOR THE APPLICATION OF WHITE LIGHT FOR THERAPEUTIC PURPOSE.
ES509179A0 (en) "A METHOD OF MANUFACTURE OF A PHARMACEUTICAL COMPOSITION OF DELAYED DELIVERY IN THE FORM OF PILLS CONTAINING AS A THERAPEUTIC AGENT IBUPROFEN OR FLURBIPROFEN".
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
DE3578597D1 (en) 4-PHENYLPHTHALAZINE DERIVATIVES, THE PRODUCTION THEREOF AND THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FI920428A0 (en) ETT PODOFYLLOTOXINPREPARAT SOM INNEHAOLLER TRIGLYSERIDER.
SE8501312L (en) ORAL DOSAGE FORM FOR ETOPSIDE
NO801759L (en) PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION AND PROCEDURE FOR PREPARING THE PREPARATION
CA2162670A1 (en) High dose formulations of mycophenolate mofetil, mycophenolic acid and ranolazine
ATE8460T1 (en) PHARMACEUTICAL PREPARATIONS AND THEIR MANUFACTURE.
FI841739A0 (en) HETEROCYKLYLLAOGALKYL-PENEM- FOERENINGAR, DESSA FOERENINGAR INNEHAOLLANDE PHARMACEUTICAL PREPARATION OF THE MEDICINAL PRODUCT.
IT8421319V0 (en) PERFECTED CAPSULE FOR SAFETY CLOSURES OF MEDICINAL USE BOTTLES.
ES268408Y (en) VAPORIZING DEVICE FOR MEDICINAL PLANT ESSENCES WITH THERAPEUTIC EFFECTS.
IT8219453A0 (en) PHARMACEUTICAL COMPOSITION ANALGESIC, ANTIPYRETIC AND ANTI-INFLAMMATORY SUITABILITY AND PROCEDURE FOR THE PREPARATION OF THE ACTIVE INGREDIENT.
IT1076416B (en) "SEPARATOR" CAP, IN PARTICULAR FOR MEDICINAL AND SIMILAR PRODUCTS, IN SINGLE DOSE PACKAGE, WITH CLOSING AND GUARANTEE CAPSULE, WITH PRESET FRACTURE
IT8819541A0 (en) PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION.
IT7945204A0 (en) PHARMACEUTICAL COMPOSITION FOR THE THERAPY OF MALE STERILITY
ATE47399T1 (en) CARBOXYALKYL DIPEPIDES, THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS.

Legal Events

Date Code Title Description
FA Application withdrawn